To explore the relationship between cefiderocol pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome in critically ill patients affected by extensively drug-resistant Acinetobacter baumannii (XDR-AB) bloodstream infection (BSI) and/or ventilator-associated pneumonia (VAP).
Gatti, M., Bartoletti, M., Cojutti, P.G., Gaibani, P., Conti, M., Giannella, M., et al. (2021). A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 27, 294-298 [10.1016/j.jgar.2021.10.014].
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol
Gatti, Milo;Bartoletti, Michele;Cojutti, Pier Giorgio;Gaibani, Paolo;Giannella, Maddalena;Viale, Pierluigi;Pea, Federico
2021
Abstract
To explore the relationship between cefiderocol pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome in critically ill patients affected by extensively drug-resistant Acinetobacter baumannii (XDR-AB) bloodstream infection (BSI) and/or ventilator-associated pneumonia (VAP).| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213716521002290-main.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
495.06 kB
Formato
Adobe PDF
|
495.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
